---
document_datetime: 2023-09-21 18:18:24
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_en.pdf
document_name: nivolumab-bms-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8451165
conversion_datetime: 2025-12-26 08:59:47.21882
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU Number        | Invented name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging   | Content   | Pack size   |
|------------------|-----------------|------------|---------------------------------------|---------------------------|-----------------------|-----------|-------------|
| EU/1/15/1026/001 | Nivolumab BMS   | 10 mg/ml   | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 4 ml      | 1 vial      |
| EU/1/15/1026/002 | Nivolumab BMS   | 10 mg/ml   | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 10 ml     | 1 vial      |

Medicinal product no longer authorised